FinTechsDepot

FedNow Payments Are Added to Dragonfly Financial Technologies’ Digital…

Admin Apr 24, 2024

FinTech company Dragonfly Financial Technologies Corp., which specializes in digital banking and treasury…

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-13T11:02:00Z

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

Andera Partners Leads $20 Million Series D Financing in Rivermark Medical

2026-05-13T11:00:00Z

The FloStent™ System Promises to Redefine the BPH Care Pathway

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-05-13T11:00:00Z

NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

2026-05-13T11:00:00Z

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in...

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

2026-05-13T11:00:00Z

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

2026-05-13T11:00:00Z

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision...

Verano Submits DEA Registration Applications for State-Licensed Medical Cannabis Businesses Following Landmark Federal Rescheduling Order

2026-05-13T11:00:00Z

CHICAGO, May 13, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the Company has submitted...

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

2026-05-13T11:00:00Z

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for...

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

2026-05-13T11:00:00Z

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics...

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

2026-05-13T11:00:00Z

Investor Webcast Scheduled for 8:00 am ET

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

2026-05-13T11:00:00Z

WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today...

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

2026-05-13T11:00:00Z

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability

Seer Files Patent Infringement Lawsuit Against Nanomics

2026-05-13T11:00:00Z

Seer defends its pioneering Proteograph® Product Suite intellectual property (IP)

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-05-13T11:00:00Z

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP –

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-13T11:00:00Z

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that...

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

2026-05-13T11:00:00Z

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

2026-05-13T11:00:00Z

REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare...

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

2026-05-13T10:50:00Z

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis -

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

2026-05-13T10:30:00Z

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

2026-05-13T10:30:00Z

DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of...

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

2026-05-13T10:01:00Z

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-13T10:00:00Z

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD...

Zymeworks Announces Participation in Upcoming Investor Conferences

2026-05-13T10:00:00Z

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,...

NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies

2026-05-13T10:00:00Z

$55 Million Series B to Advance Quantum for Healthcare

HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026

2026-05-13T09:00:00Z

Tuebingen, Germany, May 13, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical data for the lead candidate darizmetinib (formerly HRX215) has been selected for a late-breaking oral presentation at the European Association for the Study...

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

2026-05-13T08:00:00Z

BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today...

Inventiva to Present Abstracts at the EASL Congress 2026

2026-05-13T06:30:00Z

Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

2026-05-13T06:05:00Z

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver...

Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference

2026-05-13T06:03:39Z

WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical...

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

2026-05-13T06:00:00Z

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data...

FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

Embedded banking but not as you know it

How Smart Money Management and Digital Trends Are Reshaping Wealth in…

INVESTMENT GUIDE Investing for your future

5 Approaches to Scaling Finance Accuracy with AI

Understanding the Financial Interest Clause

FedNow Payments Are Added to Dragonfly Financial Technologies’ Digital…